Superworth

Precision Biosciences revenue DTIL

Sales by quarter and over the last twelve months, from 2018.

Last 12 months, to Sep 30, 2026
$45M
Latest quarter, Q3 FY26
$0
−100% on a year earlier
Fiscal year 2025
$34.3M
−50% on the year before

Precision Biosciences' revenue was $45M over the twelve months to Sep 30, 2026, up 6353% on a year earlier.

In its latest quarter, Q3 FY26, it was $0, down 100% on the same quarter a year before.

Over the five fiscal years to FY2025 it grew 7% a year on average.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2025$34.3M−50%
FY2024$68.7M+41%
FY2023$48.7M+94%
FY2022$25.1M−78%
FY2021$115.5M+376%
FY2020$24.3M+9%
FY2019$22.2M+104%
FY2018$10.9Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q3 FY26$0−100%$45M
Q2 FY26$0−100%$45.1M
Q1 FY26$10.8M+37272%$45.1M
Q4 FY25$34.2M+5261%$34.3M
Q3 FY25$13K−98%$698K
Q2 FY25$18K−100%$1.3M
Q1 FY25$29K−100%$51.1M
Q4 FY24$638K−91%$68.7M
Q3 FY24$576K−96%$75.1M
Q2 FY24$49.9M+152%$87.6M
Q1 FY24$17.6M+100%$57.5M
Q4 FY23$7M−34%$48.7M

Against its peers

Companies in Healthcare nearest Precision Biosciences' size, closest first, today.

CompanyRevenue, 12 monthsGrowth
DTILPrecision Biosciences$45.1M
PDEXPro DEX$79.6M+13% a year
PLXProtalix BioTherapeutics$80.6M+30% a year
NATRNatures Sunshine Products$492M+7% a year
ELMDElectromed$73.8M+15% a year
UTMDUtah Medical Products$36.1M−7% a year
INFUInfuSystem$143.3M+2% a year
CYHCommunity Health Systems$11.7B−8% a year
EMBCEmbecta$1B−8% a year
VMDViemed Healthcare$301.6M+25% a year
KEQUKewaunee Scientific$277.2M+5% a year
Peer median$210.3M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Precision Biosciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.